US Capital Partners Provides $1 Million Line of Credit and $500,000 Term Loan for November Research Group, LLC
US Capital Partners, LLC has put in place financing to support the continued expansion of a global leader in drug safety and pharmacovigilance services and software tools.
SAN FRANCISCO, May 2014 – US Capital Partners, LLC has provided a $1.5 million credit facility for November Research Group, LLC (“November Research”), headquartered in Oakland, CA. US Capital Partners is a private investment bank that makes direct debt investments, participates in debt facilities, and arranges equity placements for small to lower middle market companies.
“We are extremely pleased with this well-structured debt financing, which is designed to support our ongoing expansion,” said Seth Warhaftig, President of November Research. “Last year, the FDA’s Center for Devices and Radiological Health selected November Research’s PRIMO software platform as the product vigilance software solution to replace its aging MAUDE system. Recently, we launched an aggressive campaign to expand our products and services into the Japanese market. As we move into the next phase of our business expansion, this new credit facility will provide the additional working capital we need to support our growth plans.”
“We are delighted to have provided $1.5 million in financing for this global leader in drug safety and pharmacovigilance solutions,” said Jeffrey Sweeney, CEO and Managing Director at US Capital Partners. “November Research is at an inflection point in its development and required additional capital to take advantage of exciting new growth opportunities for the business. US Capital Partners successfully provided a $1 million line of credit together with a $500,000 term loan to support the company’s ongoing domestic and international expansion.”
About November Research Group, LLC
November Research is a professional services firm that provides a complete spectrum of software and services in pharmacovigilance to the pharmaceutical and life science industry. The November Research team possesses extensive expertise spanning the entire pharmacovigilance industry. The firm’s services include drug safety business process transformation, solution selection, system implementation and upgrade, custom software development, and post-implementation support.
About US Capital Partners, LLC
Since 1998, US Capital Partners (www.uscapitalpartners.net) has been providing prompt, innovative, and reliable financing solutions including lending, equity financing, and debt re-structuring to businesses across the United States and abroad. US Capital Partners is a private investment bank, direct lender, co-lender, and lead financial arranger that specializes in asset-based debt for small to middle market private and public companies. The company’s innovative approach allows it to provide the best financing available, not only for companies in excellent financial condition, but also for companies that may have been refused credit by traditional lenders.
To learn more about how your business can secure the funding it needs, email Jeffrey Sweeney, CEO and Managing Director, at firstname.lastname@example.org or call (415) 889-1010.